Agenda for Day 1 - Monday 9 November, 2026Monday, 9 November 2026

Location: Therapeutic Insights Stage

Antibody-drug conjugates (ADCs) are transforming cancer treatment by delivering targeted therapy with precision, and as clinical data matures, they are attracting significant investment and partnership activity across the oncology landscape. This session examines the latest evidence on efficacy and safety, explores what the data reveals about how ADCs are reshaping treatment strategies across tumour types, and discusses which platforms and targets are capturing attention from investors and partners. With deal flow accelerating and new opportunities emerging, the session provides strategic considerations for evaluating partnerships and investments in this high-value oncology segment.